On July 23, 2025, Opus Genetics, Inc. announced a strategic partnership with the Global RDH12 Alliance to advance its gene therapy program for patients with vision loss due to retinol dehydrogenase 12 (RDH12) gene mutations. The Alliance will provide up to $1.6 million towards the development of the OPGx-RDH12 program.
This collaboration aims to accelerate the development of OPGx-RDH12, Opus’ gene therapy program targeting RDH12-LCA, a rare inherited retinal disease causing progressive vision loss. The partnership includes a risk-sharing structure and performance-based milestones.
The co-development efforts, including clinical and regulatory strategy, are targeting the filing of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) by late 2025. This funding and partnership are crucial for advancing this promising therapy for inherited childhood blindness.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.